Geneva, May 29 -- International Clinical Trials Registry received information related to the study (ChiCTR2600124919) titled 'Neoadjuvant Therapy with Nimotuzumab Combined with Immunotherapy and Chemotherapy for Early-Stage Laryngeal/Hypopharyngeal Squamous Cell Carcinoma:A Single-Arm, Prospective, Exploratory Clinical Study' on May 19.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: The Second People's Hospital of Shandong Province
Condition:
Head and neck carcinomas
squamous cell carcinoma of the larynx or hypopharynx
Intervention:
study group:Nimotuzumab injection: 400 mg on day 1, every 3 weeks (Q3W), for 2 cycles.
TPNab-paclitaxel: 260 mg/m^2 on day 1, Q3W
for 2 cycles.
Cisplatin or nedaplatin: 80 m...